President-elect Donald Trump has put forward a formal pick for the top spot at the U.S. Food and Drug Administration. | ...

For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one.

While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the ...

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...

While president-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS ...

As the biopharma industry braces for a second term under President-elect Donald Trump, speculation is swirling around the ...

Every year, Fierce’s pharma, biotech, and medtech teams come together to spotlight some of the fiercest women in life s | ...

Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. | Interim results from a late-stage trial of ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

As a council of outside experts prepares to meet Thursday to discuss AstraZeneca’s Andexxa, the FDA has flagged “major safety ...

It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...

With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it’s likely back to the ...